Genitourinary Cancers

Meta: Benjamin Garmezy, MD discusses future therapeutic prospects for patients with variant renal cell carcinoma (RCC)

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.

A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

Nikhil A. Gopal, MD, discusses future research directions for the treatment of various renal cell carcinoma histologies.

Samer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

Samer A. Srour, MB ChB, MS, discusses toxicities associated with CTX130 in advanced clear cell renal cell carcinoma.

Samer A. Srour, MB ChB, MS, discusses the utility of the CAR T-cell therapy CTX130 and unmet needs in advanced clear cell renal cell carcinoma.

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Benjamin Garmezy, MD, discusses key factors influencing treatment selection for patients with variant renal cell carcinoma.

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.